MA43178A - Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci - Google Patents

Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci

Info

Publication number
MA43178A
MA43178A MA043178A MA43178A MA43178A MA 43178 A MA43178 A MA 43178A MA 043178 A MA043178 A MA 043178A MA 43178 A MA43178 A MA 43178A MA 43178 A MA43178 A MA 43178A
Authority
MA
Morocco
Prior art keywords
methods
synthesis
treatment
drug conjugates
epothilone analogues
Prior art date
Application number
MA043178A
Other languages
English (en)
Inventor
Kyriacos C Nicolaou
Derek Rhoades
Sotirios Totokotsopoulos
Yanping Wang
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of MA43178A publication Critical patent/MA43178A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
MA043178A 2015-10-16 2016-10-14 Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci MA43178A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562242702P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
MA43178A true MA43178A (fr) 2018-09-12

Family

ID=58518025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043178A MA43178A (fr) 2015-10-16 2016-10-14 Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci

Country Status (10)

Country Link
US (1) US10874646B2 (fr)
EP (1) EP3371176A4 (fr)
JP (1) JP2018534283A (fr)
CN (1) CN108430996A (fr)
AU (1) AU2016340093A1 (fr)
BR (1) BR112018007673A2 (fr)
CA (1) CA3002027A1 (fr)
MA (1) MA43178A (fr)
MX (1) MX2018004696A (fr)
WO (1) WO2017066606A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202130620A (zh) * 2019-10-18 2021-08-16 美商富曼西公司 5-溴-2-(3-氯-2-吡啶基)-2h-吡唑-3-羧酸的製備方法
EP4045487A1 (fr) * 2019-10-18 2022-08-24 Fmc Corporation Procédés de préparation d'acide 5-bromo-2-(3-chloro-pyridin-2-yl)-2 h-pyrazole-3-carboxylique
HUE062047T2 (hu) * 2019-10-18 2023-09-28 Fmc Corp Eljárás 5-bróm-2-(3-klór-piridin-2-il)-2H-pirazol-3-karbonsav elõállítására

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
SK11452001A3 (sk) * 1999-02-11 2002-04-04 Schering Aktiengesellschaft Deriváty epotilónu, farmaceutický prípravok s ich obsahom a ich použitie
US7125893B1 (en) 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
WO2007062288A2 (fr) 2005-11-22 2007-05-31 The Scripps Research Institute Synthese chimique d'un epothilone tres puissant
PE20080316A1 (es) * 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
EP1930004A1 (fr) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Utilisation d'épothylones dans le traitement de l'ostéoporose et des maladies associées
EP2009114A1 (fr) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Procédés, kits et composés pour déterminer la réactivité au traitement d'un trouble pathologique par épothilones
CN101519404B (zh) * 2008-02-29 2016-01-20 唐莉 15环噻酮衍生物及其制备方法与应用
WO2014096551A1 (fr) * 2012-12-21 2014-06-26 Glykos Finland Oy Conjugués constitués de molécules de charge utile et de lieurs
US20140323533A1 (en) * 2013-04-29 2014-10-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases

Also Published As

Publication number Publication date
EP3371176A1 (fr) 2018-09-12
US20190022069A1 (en) 2019-01-24
CA3002027A1 (fr) 2017-04-20
US10874646B2 (en) 2020-12-29
AU2016340093A1 (en) 2018-05-10
MX2018004696A (es) 2018-11-29
JP2018534283A (ja) 2018-11-22
WO2017066606A1 (fr) 2017-04-20
EP3371176A4 (fr) 2019-09-04
CN108430996A (zh) 2018-08-21
BR112018007673A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
IL274938A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
MA45192A (fr) Traitement d'association
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
MA49715A (fr) Oligomères et conjugués d'oligomères
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
FI20145492A (fi) Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen
MA48709A (fr) Conjugués de médicament à base de silicium et leurs procédés d'utilisation
MA44391A (fr) Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
MA44987A (fr) Formulations de médicaments améliorées
FR3056393B1 (fr) Orthese d'extension de machoires
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
MA43178A (fr) Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
MA51295A (fr) Dosage, procédé et traitement d'alpha-synucléinopathies
DK3275457T3 (da) Farmaceutisk sammensætning omfattende silybin og pu'er-te-essens
MA42264A (fr) Procédé de préparation d'oltipraz
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine
BR112018005305A2 (pt) agente profilático ou terapêutico da queratite fungal
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
MA41868A (fr) Pastille retard et procédés s'y rapportant